|
|
 |
|
Viewing report
|
|
|
|
ALK-Abello A/S: Company Profile and SWOT Analysis
iCD Research, Sep 2011, Pages: 33
Synopsis
ICD Research's 'ALK-Abello A/S: Company Profile and SWOT Analysis' contains in depth information and data about the company and its operations. The profile contains a company overview, business description, financial ratios, SWOT analysis, key facts, information on products and services, details of locations and subsidiaries, plus information on key news events affecting the company.
Summary
This SWOT analysis and company profile is a crucial resource for industry executives and anyone looking to gain a better understanding of the company's business.
ICD Research's 'ALK-Abello A/S: Company Profile and SWOT Analysis' report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format.
ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
Scope
- Examines and identifies key information and issues about ALK-Abello A/S for business intelligence requirements
- Studies and presents the company's strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported
- Provides analysis on financial ratios of the company
- The profile also contains information on business operations, company history, major products and services, prospects, key competitors, key employees, locations and subsidiaries
Reasons To Buy
- Quickly enhance your understanding of the company
- Gain insight into the marketplace and a better understanding of internal and external factors which could impact the industry
- Increase business/sales activities by understanding your competitors’ businesses better
- Recognize potential partnerships and suppliers
- Obtain yearly profitability figures
Key Highlights
ALK-Abello A/S (ALK) is a pharmaceutical company engaged in developing products for allergy treatment, diagnosis and prevention. The company is principally focused on developing allergy vaccination (immunotherapy). ALK is the first company to introduce tablet based allergy vaccines. GRAZAX is the first tablet-based allergy vaccine developed by the company. ALK’s product portfolio comprises of Allergy diagnostics products (Soluprick SQ), Emergency treatment products (EpiPen) and Allergy vaccines. Further, the company offers three types of allergy vaccines, namely, tablet vaccines (GRAZAX), sublingual vaccines (SLITone), and subcutaneous vaccines (Alutard SQ). The company has five tablet-based vaccines, Grass, House dust mites, Ragweed, Tree, and Cat tablets under clinical development. ALK through its subsidiaries has its operations spread across 13 countries in the world. The company is headquartered in Horsholm, Denmark.
|
|
|
|
